Insider Selling: Teva Pharmaceutical Industries Limited (NYSE:TEVA) Insider Sells $254,766.06 in Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.30 on Friday. The stock’s 50-day moving average is $14.01 and its two-hundred day moving average is $12.01. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. Teva Pharmaceutical Industries Limited has a 1 year low of $7.09 and a 1 year high of $17.13.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the business. iA Global Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth $1,436,000. California State Teachers Retirement System boosted its stake in shares of Teva Pharmaceutical Industries by 13.9% during the first quarter. California State Teachers Retirement System now owns 1,374,231 shares of the company’s stock worth $19,390,000 after buying an additional 167,786 shares during the period. Industrial Alliance Investment Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $54,000. Iron Triangle Partners LP increased its position in Teva Pharmaceutical Industries by 113.1% in the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after acquiring an additional 1,469,864 shares during the period. Finally, Maple Rock Capital Partners Inc. lifted its position in Teva Pharmaceutical Industries by 68.3% during the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after acquiring an additional 1,770,000 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TEVA. Piper Sandler reissued an “overweight” rating and set a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a research note on Friday, March 8th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 10th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their target price for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Finally, The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $14.22.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.